Keyphrases
Cost-effectiveness
100%
Proton Therapy
100%
Photon Therapy
100%
Pediatric Medulloblastoma
100%
Adverse Events
14%
Coronary Artery Disease
14%
Pediatric Patients
14%
Standard of Care
14%
Health Status
14%
Ototoxicity
14%
Sensitivity Analysis
14%
Risk Estimation
14%
Medicare Data
14%
Cost Analysis
14%
Medulloblastoma
14%
Societal Perspective
14%
Healthy Tissue
14%
Incremental Cost-effectiveness Ratio
14%
Growth Hormone Deficiency
14%
Quality-adjusted Life Years
14%
Life-years Gained
14%
Institutional Data
14%
Adverse Health
14%
Risk Data
14%
Medulloblastoma Survivors
14%
Probabilistic Sensitivity Analysis
14%
Longitudinal Outcomes
14%
Cost-effective Strategy
14%
Investment Cost
14%
Risk Parameters
14%
Monte Carlo Simulation Model
14%
Secondary Malignant Neoplasm
14%
Capital Investment
14%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Health Care Cost
100%
Pediatrics
100%
Proton Therapy
100%
Medulloblastoma
100%
Photon Therapy
100%
Base
14%
Malignant Neoplasm
14%
Adverse Event
14%
Pediatrics Patient
14%
Coronary Artery Disease
14%
Medicare
14%
Health Status
14%
Ototoxicity
14%
Monte Carlo Method
14%
Quality Adjusted Life Year
14%
Growth Hormone Deficiency
14%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Medulloblastoma
100%
Proton Therapy
100%
Photon Therapy
100%
Base
14%
Medicare
14%
Coronary Artery Disease
14%
Adverse Event
14%
Health Status
14%
Malignant Neoplasm
14%
Pediatrics Patient
14%
Health Care Quality
14%
Incremental Cost-Effectiveness Ratio
14%
Quality Adjusted Life Year
14%
Monte Carlo Method
14%
Growth Hormone Deficiency
14%
Ototoxicity
14%
Pharmacology, Toxicology and Pharmaceutical Science
Medulloblastoma
100%
Malignant Neoplasm
25%
Adverse Event
25%
Base
25%
Coronary Artery Disease
25%
Health Status
25%
Ototoxicity
25%
Growth Hormone Deficiency
25%